The Pharma Data

MARCH 31, 2022

A significant part of these investments will be made for enhanced capacities in biotechnology, further strengthening the company’s cell and gene therapy production as well as in the expansion of its manufacturing site in Berkeley, USA. Germany will remain an important strategic manufacturing location for the company.

Production 52

Production Manufacturing Hormones Gene Therapy 52

Delveinsight

JULY 30, 2020

The buildup in adrenal glands leads to the insufficient hormonal response, thus leading to several of the symptoms such as deficiency of steroid hormones (mainly cortisol and aldosterone), impaired cortisol secretion, and others that are harbingers of the disease. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

MAY 23, 2024

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Trials 52

The Pharma Data

MARCH 22, 2021

Novartis has established global expertise and specialized supply chain and manufacturing capabilities across its network of four radioligand therapy production sites, and is further increasing capacity to ensure delivery of radioligand therapies like 177 Lu-PSMA-617 to patients in need. About Advanced Prostate Cancer.

Hormones 52

Hormones Gene Therapy Medicine Trials 52

pharmaphorum

JANUARY 10, 2023

The one-shot therapy is expected to provide long-lasting effects, reduce the number of bleeds experienced by patients, and reduce the need Factor VIII replacement therapy.

Drugs 52

Drugs Gene Therapy Antibody Insulin 52

The Pharma Data

MARCH 11, 2021

These include, in particular, the cancer drug Nubeqa , the cardiovascular drugs vericiguat (marketed in the United States under the brand name Verquvo ) and finerenone, and elinzanetant for the non-hormonal treatment of frequent symptoms of the menopause.

Sales 52

Sales Gene Therapy Marketing Gene 52

The Pharma Data

JANUARY 7, 2021

To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. “In addition to understanding patient biology better, you have to create new technologies,” Nestle said. Another area where Sanofi is investing is through the Expanded Genetic Alphabet platform it gained at the end of 2019 through the $2.5

Protein 52

Protein Antibody Genetics Gene Therapy 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

APRIL 28, 2022

These included setting their sights beyond haemophilia and growth hormone deficiencies into the wider, but still focused, spaces of red blood and endocrine disorders; a commercial enhancement program helping the company to launch medicines faster and with more impact; and a number of acquisitions that have given the company footholds in new treatment (..)

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Institute hormone replacement therapy for endocrinopathies as warranted. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. Institute hormone replacement therapy for endocrinopathies as warranted. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

MAY 15, 2021

I was recently reminded of my journey out of the HCT nightmare as I watched a documentary about gene therapy. Gene therapy is a huge deal – some gene therapies are already achieving jaw-dropping results for people with previously untreatable illnesses. It’s fascinating stuff.

Bacteria 52

Bacteria Gene Gene Therapy Gene Expression 52

Pharmaceutical Technology

APRIL 24, 2023

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130